Physician profile
Fen Liang
NPI 1780843953
$12,258.38
in general payments reported to CMS, 2019-2025
35 companies · $1,935 in 2025
The $1,935 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,501 · 2021: $2,103 · 2022: $1,692 · 2023: $1,625 · 2024: $1,902 · 2025: $1,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,411 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,026.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,711.19 | 2021-2025 | |
| Pfizer INC. | $870.97 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $766.86 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $688.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $482.82 | 2021-2025 | Givlaari, Oxlumo |
| Janssen Pharmaceuticals, INC | $441.73 | 2019-2022 | |
| Lilly USA, LLC | $418.05 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $383.09 | 2019-2023 | |
| Amgen INC. | $340.97 | 2019-2025 | Repatha, Repatha, Otezla |
| Currax Pharmaceuticals LLC | $318.98 | 2021-2024 | Contrave, Onzetra Xsail, Nexletol |
| Allergan, INC. | $318.13 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $268.20 | 2020-2021 | |
| Exact Sciences Corporation | $257.46 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $227.10 | 2019-2025 | Arexvy, Shingrix |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fen Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.